International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
David Isenberg(Regenerative Medicine Institute), Frederick W. Miller(National Institutes of Health), Robert G. Cooper, Clarissa Pilkington(Great Ormond Street Hospital), Lisa G. Rider(United States Food and Drug Administration), Michael R. Ehrenstein, David L. Scott(St Michaels Hospital), Paul H. Plötz(National Institutes of Health), Vernon T. Farewell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Chester V. Oddis(University of Pittsburgh), Jiří Vencovský(Charles University), Michael G. Hanna(National Hospital for Neurology and Neurosurgery), Elizabeth Allen(London School of Hygiene & Tropical Medicine), Ingrid E. Lundberg(Karolinska University Hospital)
Cited by 367
Related Papers
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Therapy of Lupus Nephritis
|New England Journal of Medicine|1986|1.2k
A New Approach to the Classification of Idiopathic Inflammatory Myopathy
|Medicine|1991|974
Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry
|Journal of the American College of Cardiology|1998|748
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726